Analysts’ Top Healthcare Picks: Liquidia Technologies (LQDA), Healthequity (HQY)
TipRanks (Fri, 5-Jun 9:20 AM ET)
EyePoint’s CAPRI Phase 3 Trial Targets Long-Acting Relief in Diabetic Eye Disease
TipRanks (Wed, 3-Jun 12:33 PM ET)
EyePoint Announces Participation at Upcoming Investor Conferences
Globe Newswire (Tue, 19-May 7:00 AM ET)
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire (Mon, 18-May 7:00 AM ET)
Globe Newswire (Thu, 14-May 7:00 AM ET)
EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
Globe Newswire (Wed, 6-May 7:00 AM ET)
EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
Globe Newswire (Wed, 29-Apr 7:00 AM ET)
EyePoint’s Inducement Options Grant Signals Confidence Amid Advancing Retinal Drug Pipeline
Market Chameleon (Tue, 17-Feb 5:31 AM ET)
EyePoint’s $150 Million Public Offering Fuels Late-Stage Trials and Pipeline Expansion
Market Chameleon (Wed, 15-Oct 4:22 AM ET)
Market Chameleon (Wed, 5-Feb 3:40 AM ET)
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Eyepoint trades on the NASDAQ stock market under the symbol EYPT.
As of June 8, 2026, EYPT stock price declined to $11.45 with 666,224 million shares trading.
EYPT has a beta of 2.17, meaning it tends to be more sensitive to market movements. EYPT has a correlation of 0.15 to the broad based SPY ETF.
EYPT has a market cap of $959.46 million. This is considered a Small Cap stock.
Last quarter Eyepoint reported $696,000 in Revenue and -$.99 earnings per share. This beat revenue expectation by $353,736 and missed earnings estimates by -$.19.
In the last 3 years, EYPT traded as high as $30.99 and as low as $3.91.
The top ETF exchange traded funds that EYPT belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
EYPT has outperformed the market in the last year with a return of +38.8%, while the SPY ETF gained +25.9%. However, in the most recent history, EYPT shares have underperformed the stock market with its stock returning -27.3% in the last 3 month period and -11.4% for the last 2 week period, while SPY has returned +8.8% and -0.9%, respectively.
EYPT support price is $11.32 and resistance is $12.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EYPT shares will trade within this expected range on the day.